IMV Inc. (IMVIQ) Research

IMV Inc. is a biotechnology firm focused on developing cancer treatments, currently in the clinical trial phase. It leverages its proprietary DPX immune-modulating technology platform to create a range of therapeutic candidates aimed at both solid and blood-related cancers. Its primary investigational therapy, maveropepimut-S, is an immunotherapy built on the DPX platform, designed to target cells that express survivin. This compound is currently undergoing Phase II clinical evaluations for conditions such as diffuse large B-cell lymphoma, ovarian cancer, as well as solid tumors of the bladder, liver, and those exhibiting high microsatellite instability (MSI-H). Additionally, maveropepimut-S is in Phase I trials for breast cancer. Other developments include DPX-SurMAGE, which is in Phase I trials for bladder cancer, along with candidates like DPX-COVID-19 and DPX-RSV, which are being explored for infectious diseases. Previously known as Immunovaccine Inc., the company adopted the name IMV Inc. in May 2018. Established in 2000, IMV Inc. maintains its headquarters in Dartmouth, Canada.

Market snapshot

Symbol
IMVIQ
Price
$0.00
Day change
-90.00%
Market cap
$9.3M
P/E ratio
-0.18x
52-week range
1.0E-5-1.0
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Allena Pharmaceuticals, Inc. (ALNAQ)
  • Primo Nutraceuticals Inc. (BUGVF)
  • Green Hygienics Holdings Inc. (GRYN)
  • Indie Ranch Media, Inc. (INDR)
  • LifeHOUSE Holdings, LLC (LHRP)
  • Photoelectron Corp. (PECN)
  • QMed, Inc. (QMED)
  • ReGen Biologics Inc. (RGBOQ)

Open IMV Inc. (IMVIQ) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.